GentiBio

📍 Cambridge, United States🗓 Founded 2020👥 83 employees💰 Last funded 2021
Biotechnology🌐 GentiBio.com
Website LinkedIn
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBios proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in GentiBio?
GentiBio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did GentiBio last raise funding?
The most recent investment in GentiBio recorded on gritt.io was in 2021.
When was GentiBio founded?
GentiBio was founded in 2020.
What industry is GentiBio in?
GentiBio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is GentiBio based?
GentiBio is headquartered in Cambridge, United States.